Tandem Diabetes Care, Inc. (NASDAQ:TNDM) EVP Acquires $12,363.68 in Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) EVP Mark David Novara acquired 532 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were bought at an average cost of $23.24 per share, with a total value of $12,363.68. Following the transaction, the executive vice president now directly owns 532 shares in the company, valued at $12,363.68. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Tandem Diabetes Care Price Performance

TNDM opened at $30.51 on Friday. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 52-week low of $18.45 and a 52-week high of $53.69. The company has a 50 day moving average of $36.42 and a two-hundred day moving average of $41.35. The company has a market cap of $2.00 billion, a P/E ratio of -15.93 and a beta of 1.36.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million during the quarter, compared to the consensus estimate of $224.14 million. During the same period in the previous year, the firm earned ($0.38) earnings per share. Tandem Diabetes Care’s revenue for the quarter was up 31.4% on a year-over-year basis. On average, analysts expect that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of research analyst reports. Wells Fargo & Company increased their price objective on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. The Goldman Sachs Group began coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 price target on the stock. Robert W. Baird cut their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. Barclays lifted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Finally, Royal Bank of Canada began coverage on shares of Tandem Diabetes Care in a research report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and an average price target of $54.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Tandem Diabetes Care by 0.4% in the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after purchasing an additional 30,664 shares during the period. State Street Corp boosted its stake in shares of Tandem Diabetes Care by 3.2% in the third quarter. State Street Corp now owns 2,655,736 shares of the medical device company’s stock valued at $112,630,000 after purchasing an additional 83,172 shares during the period. Fred Alger Management LLC boosted its stake in shares of Tandem Diabetes Care by 45.2% in the second quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock valued at $87,595,000 after purchasing an additional 677,036 shares during the period. Bellevue Group AG boosted its stake in shares of Tandem Diabetes Care by 2.0% in the first quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company’s stock valued at $71,949,000 after purchasing an additional 39,571 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Tandem Diabetes Care by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,525,816 shares of the medical device company’s stock valued at $64,722,000 after purchasing an additional 18,187 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.